Sight Sciences, which provides medical and surgical devices for underserved eye diseases, raised $240 million by offering 10 million shares at $24, the high end of the upwardly revised range of $23 to $24.
The company had originally filed to raise $150 million by offering 7 million shares at a range of $20 to $23, before upping the proposed share offering and range early on Wednesday. At pricing, the company raised 60% more than originally anticipated.
Sight Sciences currently markets two products. Its OMNI Surgical System is a handheld, single-use therapeutic device that allows ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients via a minimally invasive surgery. TearCare is a wearable, open-eye system designed to apply localized heat to eyelids for the treatment of Dry Eye Disease.
The Menlo Park, CA-based company plans to list on the Nasdaq under the symbol SGHT. Morgan Stanley, BofA Securities, Citi, and Piper Sandler acted as joint bookrunners on the deal.
